{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:52:03Z","timestamp":1785423123898,"version":"3.56.0"},"reference-count":59,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Key R&amp;D Projects in Hebei Province, China","award":["20377726D"],"award-info":[{"award-number":["20377726D"]}]},{"name":"the Key R&amp;D Projects in Hebei Province, China","award":["20221221"],"award-info":[{"award-number":["20221221"]}]},{"name":"the Key Research Projects of Medical Science in Hebei Province, China","award":["20377726D"],"award-info":[{"award-number":["20377726D"]}]},{"name":"the Key Research Projects of Medical Science in Hebei Province, China","award":["20221221"],"award-info":[{"award-number":["20221221"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Fluoropyrimidine plus platinum (FP) and taxanes plus platinum (TP) are standard treatments for esophageal cancer (EC). This systematic review and meta-analysis aim to explore the difference in the therapeutic effect and toxicity of FP and TP regimens in EC patients. PubMed, Embase, and Cochrane were fully searched and analyzed to find relevant articles on EC patients treated with FP and TP regimens up to 22 March 2022. Thirty-one studies, with a total of 3432 participants, were included in this review. The primary outcomes showed that the prognosis and therapeutic efficacy of TP groups were better than those of FP groups for the EC patients treated with definitive chemoradiotherapy treatment (3-year OS: RR: 1.25, 95% CI: 1.08\u20131.44, p = 0.003; 3-year PFS: RR: 1.43, 95% CI: 1.17\u20131.75, p = 0.0006; ORR: RR: 1.17, 95% CI: 1.06\u20131.29, p = 0.001). However, TP therapy was significantly correlated with a higher incidence of leukopenia and thrombocytopenia (p &lt; 0.05). In the preoperative neoadjuvant chemoradiotherapy group, these two groups had a similar survival time (p &gt; 0.05). The FP regimen corresponded to a higher incidence of thrombocytopenia, while the TP regimen was associated with an increased incidence of febrile leukopenia (p &lt; 0.05). Therefore, TP regimens could generate both superior clinical response and survival benefits when compared with FP regimens in EC patients undergoing definitive chemoradiotherapy.<\/jats:p>","DOI":"10.3390\/curroncol29090519","type":"journal-article","created":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T22:12:43Z","timestamp":1663539163000},"page":"6610-6627","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"29","author":[{"given":"Yue","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chensi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5111-5444","authenticated-orcid":false,"given":"Zhanjun","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"ref_1","first-page":"S253","article-title":"Current management of esophageal cancer","volume":"6","author":"Thomas","year":"2014","journal-title":"J. Thorac. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5732\/cjc.011.10390","article-title":"Epidemiologic differences in esophageal cancer between Asian and western populations","volume":"31","author":"Zhang","year":"2012","journal-title":"Chin. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Yamashita, H., Seto, Y., Takenaka, R., Okuma, K., Kiritooshi, T., Mori, K., Yamada, K., Fukuda, T., Kaminishi, M., and Abe, O. (2017). Survival comparison between radical surgery and definitive chemoradiation in 267 esophageal squamous cell carcinomas in a single institution: A propensity-matchedstudy. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0177133"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"v46","DOI":"10.1093\/annonc\/mdq163","article-title":"Esophageal cancer: Clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Stahl","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1200\/JCO.2009.22.2083","article-title":"Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer","volume":"27","author":"Allum","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.athoracsur.2010.04.061","article-title":"Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer","volume":"90","author":"Swisher","year":"2010","journal-title":"Ann. Thorac. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"Hulshof","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/jjco\/hyv119","article-title":"Systematic review and network meta-analysis: Neoadjuvant chemoradiotherapy for locoregional esophageal cancer","volume":"45","author":"Huang","year":"2015","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/1097-0215(20000620)90:3<113::AID-IJC1>3.0.CO;2-C","article-title":"Combining taxanes with radiation for solid tumors","volume":"90","author":"Choy","year":"2000","journal-title":"Int. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0360-3016(92)90888-O","article-title":"Taxol: A novel radiation sensitizer","volume":"22","author":"Tishler","year":"1992","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/jnci\/88.18.1308","article-title":"Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel","volume":"88","author":"Milross","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3892\/or.2021.7973","article-title":"Melatonin sensitizes esophageal cancer cells to 5fluorouracil via promotion of apoptosis by regulating EZH2 expression","volume":"45","author":"Zhang","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3390\/molecules13081551","article-title":"5-Fluorouracil: Mechanisms of resistance and reversal strategies","volume":"13","author":"Zhang","year":"2008","journal-title":"Molecules"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3748\/wjg.v16.i13.1649","article-title":"Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma","volume":"16","author":"Lv","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2147\/DDDT.S189514","article-title":"The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: A meta-analysis of clinical studies","volume":"13","author":"Wang","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/jso.21063","article-title":"Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non-randomized study","volume":"98","author":"Hsu","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10330-013-1187-x","article-title":"Randomized trial of weekly docetaxel and cisplatin combined with concurrent 3DCRT in patients with locally advanced esophageal cancer","volume":"12","author":"Bai","year":"2013","journal-title":"Chin.-Ger. J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100736","DOI":"10.1016\/j.tranon.2019.12.008","article-title":"Comparison of a concurrent fluorouracil-based regimen and a taxane-based regimen combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma","volume":"13","author":"Huang","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.2147\/DDDT.S105441","article-title":"Comparison of cisplatinum\/paclitaxel with cisplatinum\/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients","volume":"10","author":"Hu","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13014-018-1085-z","article-title":"Comparison of definite chemoradiation therapy with carboplatin\/paclitaxel or cisplatin\/5-fluoruracil in patients with squamous cell carcinoma of the esophagus","volume":"13","author":"Pigorsch","year":"2018","journal-title":"Radiat. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.3747\/co.24.3677","article-title":"Shifting practice in definitive chemoradiation for localized esophageal cancer","volume":"24","author":"Qu","year":"2017","journal-title":"Curr. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.7150\/jca.13547","article-title":"A retrospective comparison of taxane and fluorouracil-based chemoradiotherapy in patients with Inoperable esophageal squamous cell carcinoma","volume":"7","author":"Sun","year":"2016","journal-title":"J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/annonc\/mdt589","article-title":"A comparison of carboplatin with paclitaxel and cisplatinum with 5-fluorouracil in definitive chemoradiotherapy in esophageal cancer patients","volume":"25","author":"Honing","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"37080","DOI":"10.18632\/oncotarget.16180","article-title":"Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma","volume":"8","author":"Fang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/imj.12773","article-title":"Comparison of efficacy and toxicity profiles between paclitaxel\/lobapoatin- and cisplatin\/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer","volume":"45","author":"Yang","year":"2015","journal-title":"Intern. Med. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s12032-012-0228-6","article-title":"Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: A randomized clinical study","volume":"29","author":"Zhao","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.7150\/jca.20053","article-title":"A phase II randomized controlled trial: Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with oesophageal squamous cell carcinoma","volume":"8","author":"Zhu","year":"2017","journal-title":"J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"44686","DOI":"10.18632\/oncotarget.9301","article-title":"Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: A propensity score-matched analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.21873\/invivo.12638","article-title":"Paclitaxel and carboplatin versus cisplatin and 5-fluorouracil in concurrent chemoradiotherapy in patients with esophageal cancer","volume":"35","author":"Su","year":"2021","journal-title":"In Vivo"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000510446","article-title":"Chemoradiotherapy using carboplatin plus paclitaxel versus cisplatin plus fluorouracil for esophageal or gastroesophageal junction cancer","volume":"99","author":"Jiang","year":"2021","journal-title":"Oncology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"8300","DOI":"10.1002\/cam4.4025","article-title":"Definitive concurrent chemoradiotherapy with paclitaxel plus carboplatin is superior to cisplatin plus 5-fluorouracil in patients with inoperable esophageal squamous cell carcinoma using retrospective, real-world evidence","volume":"10","author":"Hsieh","year":"2021","journal-title":"Cancer Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Dr\u00f6ge, L.H., Karras, P.J., Guhlich, M., Schirmer, M.A., Ghadimi, M., Rieken, S., Conradi, L.C., and Leu, M. (2021). Preoperative radiochemotherapy in esophageal squamous cell cancer with 5-fluorouracil\/cisplatin or carboplatin\/paclitaxel: Treatment practice over a 20-year period and implications for the individual treatment modalities. Cancers, 13.","DOI":"10.3390\/cancers13081834"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/SLA.0000000000004329","article-title":"Neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil (PF) versus carboplatin and paclitaxel (cross regimen) for esophageal equamous cell carcinoma (ESCC): A propensity score-matched study","volume":"272","author":"Wong","year":"2020","journal-title":"Ann. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"272","DOI":"10.4103\/ijmpo.ijmpo_16_16","article-title":"Preoperative chemoradiation in carcinoma esophagus: Experience from a tertiary cancer center in India","volume":"39","author":"Bajwa","year":"2018","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/jjco\/hyx060","article-title":"Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy","volume":"47","author":"Xi","year":"2017","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/dote\/dox025","article-title":"A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer","volume":"30","author":"Sanford","year":"2017","journal-title":"Dis. Esophagus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/jso.24786","article-title":"Influence of tumor response and treatment schedule on the distribution of tumor recurrence in esophageal cancer patients treated with neoadjuvant chemoradiotherapy","volume":"116","author":"Jipping","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/dote\/dox015","article-title":"Neoadjuvant chemoradiotherapy with concurrent cisplatin\/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin\/paclitaxel in patients with locally advanced esophageal cancer","volume":"30","author":"Haisley","year":"2017","journal-title":"Dis. Esophagus"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/jamasurg.2016.2821","article-title":"Comparative effectiveness of preoperative treatment regimens in patientswith potentially resectable esophageal cancer","volume":"152","author":"Duff","year":"2017","journal-title":"JAMA Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/dote.12243","article-title":"Analysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancer","volume":"28","author":"Boggs","year":"2015","journal-title":"Dis. Esophagus"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/dote.12110","article-title":"Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma","volume":"27","author":"Blom","year":"2014","journal-title":"Dis. Esophagus"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1442-2050.2011.01220.x","article-title":"Complete response to preoperative chemoradiation and survival in esophageal cancer: A pooled analysis of three single-institution phase II trials","volume":"25","author":"Orditura","year":"2012","journal-title":"Dis. Esophagus"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1200\/JCO.2000.18.10.2032","article-title":"Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy","volume":"18","author":"Adelstein","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13014-017-0904-y","article-title":"Comparison of neoadjuvant chemoradiation with carboplatin\/paclitaxel or cisplatin\/5-fluoruracil in patients with squamous cell carcinoma of the esophagus","volume":"12","author":"Pigorsch","year":"2017","journal-title":"Radiat. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12032-017-1017-z","article-title":"Tolerability and efficacy of concurrent chemoradiotherapy comparing carboplatin\/paclitaxel versus platinum\/5-FU regimen for locally advanced esophageal and esophagogastric junction cancers","volume":"34","author":"Tamtai","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2016.11.031","article-title":"NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin\/capecitabine or carboplatin\/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma","volume":"74","author":"Mukherjee","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6423297","DOI":"10.1155\/2016\/6423297","article-title":"Predictors of survival in esophageal squamous cell carcinoma with pathologic major response after neoadjuvant chemoradiation therapy and surgery: The impact of chemotherapy protocols","volume":"2016","author":"Li","year":"2016","journal-title":"BioMed Res. Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/1748-717X-8-241","article-title":"Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: Clinical efficacy and failure pattern","volume":"8","author":"Bao","year":"2013","journal-title":"Radiat. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1748-717X-7-93","article-title":"Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer","volume":"7","author":"Zhang","year":"2012","journal-title":"Radiat. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (cross): Long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3727\/096504016X14537290676865","article-title":"Clinical outcome in definitive concurrent chemoradiation with weekly paclitaxel and carboplatin for locally advanced esophageal and junctional cancer","volume":"23","author":"Noronha","year":"2016","journal-title":"Oncol. Res."},{"key":"ref_54","unstructured":"NCCN (2022, March 22). Practise Guidelines in Oncology-Esophageal and Esophagogastric Junction Cancers. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/esophageal.pdf."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1442-2050.2009.01003.x","article-title":"Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esopheageal carcinoma","volume":"23","author":"Li","year":"2010","journal-title":"Dis. Esophagus"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejca.2020.11.039","article-title":"Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)","volume":"144","author":"Li","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.2217\/fon-2021-0632","article-title":"RATIONALE 311, Tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma","volume":"17","author":"Yu","year":"2021","journal-title":"Future Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.21873\/anticanres.12940","article-title":"Cisplatin substitution with carboplatin during radical chemoradiotherapy for oesophagogastric carcinoma: Outcomes from a tertiary centre","volume":"38","author":"Athauda","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","article-title":"INT 0123 (radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy","volume":"20","author":"Bruce","year":"2002","journal-title":"J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/9\/519\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:32:37Z","timestamp":1760142757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/9\/519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":59,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["curroncol29090519"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29090519","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]}}}